PAMM Foundation Outsources Its Laboratory Activities for Pathology and Medical Microbiology (“PAMM”) to Eurofins Clinical Diagnostics Netherlands
May 09 2022 - 12:15AM
Business Wire
Eurofins Scientific (EUFI.PA), a global scientific leader in
bioanalytical testing, announces that it has successfully signed an
agreement with Stichting PAMM Laboratoria voor Pathologie en
Medische Microbiologie (“PAMM”), a medical microbiology and
pathology laboratory diagnostics company in The Netherlands.
PAMM serves 6 hospitals in The Netherlands, including 2
top-rated clinical oncology centers, general practitioners and
independent treatment centers. The lab specializes in medical
microbiology and pathology and was the first in The Netherlands to
have implemented full digital pathology. PAMM employs over 265
employees and pathologists and will complement Eurofins’
industry-leading global clinical testing offering. Through
combining forces, PAMM will be able to further improve quality to
clients and service to patients in the Dutch healthcare system.
The agreement includes a commitment by Eurofins to invest in the
laboratory, R&D, innovation, employee development and job
security. The agreement has been approved by the Dutch Healthcare
authority (NZa) and The Netherlands Authority for Consumers and
Markets (ACM, Merger Control).
Comment from Dr. Gilles Martin, Eurofins CEO: “We are
very pleased to welcome PAMM and its team of outstanding
specialists and laboratory technicians to the Eurofins Group. This
agreement reinforces the Group’s broad innovative test offering to
hospitals and practitioners in The Netherlands, strengthens
Eurofins geographic offering in the clinical testing market, and
enhances our ability to deploy the latest scientific advances to
benefit patients.”
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With 58,000 staff across a network of 900 laboratories in 54
countries, Eurofins’ companies offer a portfolio of over 200,000
analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220508005100/en/
For further information: Bernard Wang ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024